Drug profile · INN
bictegravir sodium
BIKTARVY
bictegravir sodium (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bictegravir sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 9
- Programs
- 1
- Data quality
- 0.84
Quick answer
bictegravir sodium (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 integrase inhibitor
Primary target: Human immunodeficiency virus type 1 integrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12226429
Highly active compounds against COVID-19
granted -
US 11813278
Highly active compounds against COVID-19
granted -
US 11738038
Highly active compounds against COVID-19
granted -
US 11707480
Highly active compounds against COVID-19
granted -
US 10888529
Vehicles for the transfection of miRNAs
granted -
US 10874687
Highly active compounds against COVID-19
granted -
US 10610597
Polycarbonates bearing aromatic N-heterocycles for drug delivery
granted -
US 9919027
Lipid nanoparticle of polymyxin
granted -
US 9717797
Polycarbonates bearing aromatic N-heterocycles for drug delivery
granted
Frequently asked questions
What is bictegravir sodium?
bictegravir sodium (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bictegravir sodium?
BIKTARVY is a marketed brand name for bictegravir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bictegravir sodium?
bictegravir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.